Journal article
Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
Abstract
Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colorectal cancer were treated with erlotinib at a continuous daily oral dose of 150 mg. Radiological evaluation was carried out every 8 weeks and tumour biopsies were performed before treatment and on …
Authors
Townsley CA; Major P; Siu LL; Dancey J; Chen E; Pond GR; Nicklee T; Ho J; Hedley D; Tsao M
Journal
British Journal of Cancer, Vol. 94, No. 8, pp. 1136–1143
Publisher
Springer Nature
Publication Date
April 2006
DOI
10.1038/sj.bjc.6603055
ISSN
0007-0920
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAntineoplastic AgentsChemotherapy, AdjuvantColorectal NeoplasmsDisease ProgressionDisease-Free SurvivalErbB ReceptorsErlotinib HydrochlorideFemaleFollow-Up StudiesHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingQuinazolinesRecurrenceRisk FactorsSignal TransductionSurvival RateTreatment Outcome